SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)
Condition: Bipolar Disorder Interventions: Drug: Lithium sulphate prolonged-release 660 mg; Drug: Lithium carbonate immediate-release 150 mg and 300 mg Sponsors: Aziende Chimiche Riunite Angelini Francesco S.p.A; Mediolanum Cardio Research Recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2017 Category: Research Source Type: clinical trials